EMERYVILLE, Calif., May 15, 2017 /PRNewswire/ -- Berkeley Lights, Inc., (BLI), a company dedicated to the development of transformational technologies for biopharmaceutical processes, announced today that Amgen has purchased additional Beacon Opto-Fluidic Platforms. The Beacon platform reduces workflow lead times and increases capacity by transforming currently fragmented microfluidic workflows into automated nanofluidic workflows. Amgen, which collaborated with BLI to develop this technology, will now expand its usage to cell line development, antibody discovery, and other research activities.
"We are pleased to see Amgen, a leader and innovator in the pharmaceutical industry, expand its adoption of the Beacon platform across discovery and development processes," said Eric Hobbs, PhD, BLI chief executive officer. "BLI is dedicated to improving biological workflows in collaboration with our partners."
About Berkeley Lights:
Berkeley Lights, Inc. (BLI) develops and commercializes platforms on which many bio-pharmaceutical, genomic, and cellular therapy applications will run. BLI launched its first commercial platform, the Beacon™*, in December 2016. The Beacon platform is ideally suited for cell line development and direct B-cell (plasma and memory cells) antibody discovery workflows. The flexibility of the Beacon platform allows users to automate biological processes and BLI is continuously developing new applications to align with its partners' requirements. BLI's technologies make it possible for customers to accelerate learning and dramatically improve workflows.
For more information, visit http://www.berkeleylights.com/.
* For Research Use Only. Not for use in diagnostic procedures.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/berkeley-lights-inc-announces-expanded-adoption-of-the-beacon-opto-fluidic-platform-300457234.html
SOURCE Berkeley Lights, Inc.